Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) and MindWalk (NASDAQ:HYFT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Profitability
This table compares Petros Pharmaceuticals and MindWalk’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Petros Pharmaceuticals | N/A | -78.22% | -23.50% |
| MindWalk | -66.79% | -69.37% | -39.74% |
Insider and Institutional Ownership
12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Petros Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
MindWalk has a consensus price target of $5.00, suggesting a potential upside of 208.64%. Given MindWalk’s stronger consensus rating and higher possible upside, analysts plainly believe MindWalk is more favorable than Petros Pharmaceuticals.
Valuation and Earnings
This table compares Petros Pharmaceuticals and MindWalk”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Petros Pharmaceuticals | $5.11 million | 0.03 | -$8.16 million | ($1.64) | -0.00 |
| MindWalk | $17.59 million | 4.25 | -$21.69 million | ($0.20) | -8.10 |
Petros Pharmaceuticals has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Petros Pharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Summary
MindWalk beats Petros Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
